Tanya Barauskas Dorff, MD, is a Professor in the Department of Medical Oncology &#038; Therapeutics Research at City of Hope and serves as Section Chief of the genitourinary cancers program. She is an internationally recognized leader in prostate cancer, serving on the NCCN guidelines panel for prostate cancer as well as being co-chair of the SWOG Prostate Cancer committee. After graduating from UCLA Medical School and residency at Mount Sinai, she completed her hematology-oncology fellowship training at LAC-USC Medical Center, later serving as faculty at the USC Norris Comprehensive Cancer Center prior to joining City of Hope.
Dr. Dorff’s research interests in prostate cancer are focused on novel immunotherapy and combination strategies. With the support of the Prostate Cancer Foundation, she is leading a trial of a novel PSCA-targeted chimeric antigen receptor (CAR) T cell developed at the City of Hope, and has been a lead investigator for multiple additional CAR T, bispecific T cell engaging antibody, and other immunotherapy trials. She has federal and foundation funding to support multiple investigator-initiated clinical trials.
Dr. Dorff has published over 100 original research manuscripts along with more than 50 review articles and editorials in top-tier journals, including Cancer, Lancet Oncology, and Journal of Clinical Oncology. She is currently an associate editor for the journal Prostate Cancer Prostatic Diseases as well as Seminars in Urologic Oncology and acts as a reviewer for a dozen other journals.

Tanya Dorff, MD